TVRD Stock Forecast & Price Target

Tvardi Therapeutics is attractive because TTI-101 has shown direct, tissue-level STAT3 engagement in HCC, including a 100% pharmacodynamic response rate in paired biopsies and an 18% confirmed partial response rate in 17 evaluable heavily pretreated patients, both materially above the roughly <5% expected ORR in 2L HCC. The investment case is strengthened by a large unmet need across HCC lines of therapy, where existing regimens leave many patients without durable benefit, while Tvardi’s oral, targeted mechanism could address both tumor growth and immune suppression with a differentiated safety profile. The pipeline also has added durability from TTI-109, a prodrug designed to preserve systemic exposure while improving tolerability, creating multiple near-term catalysts and a credible path to broader value creation across HCC and other STAT3-driven diseases.

Tvardi Therapeutics is fundamentally challenged by its dependence on a narrow, early-stage pipeline, with no approved products and all value tied mainly to TTI-101 in HCC and an unselected-indication TTI-109. Although STAT3 is biologically validated and pY-STAT3 is seen in about 60% of HCC tumors, direct STAT3 inhibition has a long history of broad clinical failures, and the company itself notes meaningful risks that future trials may not reproduce earlier efficacy or may reveal new safety issues. Financially, the company held $25 million in cash and short-term investments as of March 31, 2026, was valued at roughly $29 million, and could still need dilutive financing because management only expects runway into 4Q26.